Literature DB >> 16423043

Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles.

Hong Shen1, Anne L Ackerman, Virginia Cody, Alessandra Giodini, Ella R Hinson, Peter Cresswell, Richard L Edelson, W Mark Saltzman, Douglas J Hanlon.   

Abstract

CD8(+) T-cell responses are critical in the immunological control of tumours and infectious diseases. To prime CD8(+) T cells against these cell-associated antigens, exogenous antigens must be cross-presented by professional antigen-presenting cells (APCs). While cross-presentation of soluble antigens by dendritic cells is detectable in vivo, the efficiency is low, limiting the clinical utility of protein-based vaccinations. To enhance the efficiency of presentation, we generated nanoparticles from a biodegradable polymer, poly(D,L-lactide-co-glycolide) (PLGA), to deliver antigen into the major histocompatibility complex (MHC) class I antigen presentation pathway. In primary mouse bone marrow-derived dendritic cells (BMDCs), the MHC class I presentation of PLGA-encapsulated ovalbumin (OVA) stimulated T cell interleukin-2 secretion at 1000-fold lower concentration than soluble antigen and 10-fold lower than antigen-coated latex beads. The microparticles also served as an intracellular antigen reservoir, leading to sustained MHC class I presentation of OVA for 72 hr, decreasing by only 20% after 96 hr, a time at which the presentation of soluble and latex bead-associated antigens was undetectable. Cytosol extraction demonstrated that antigen delivery via PLGA particles increased the amount of protein that escaped from endosomes into the cytoplasm, thereby increasing the access of exogenous antigen to the classic MHC class I loading pathway. These data indicate that the unique properties of PLGA particle-mediated antigen delivery dramatically enhance and sustain exogenous antigen presentation by MHC class I, potentially facilitating the clinical use of these particles in vaccination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423043      PMCID: PMC1782199          DOI: 10.1111/j.1365-2567.2005.02268.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  62 in total

1.  Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo.

Authors:  Lianjun Shen; Luis J Sigal; Marianne Boes; Kenneth L Rock
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

Review 2.  Cellular mechanisms governing cross-presentation of exogenous antigens.

Authors:  Anne L Ackerman; Peter Cresswell
Journal:  Nat Immunol       Date:  2004-07       Impact factor: 25.606

Review 3.  Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens.

Authors:  William R Heath; Gabrielle T Belz; Georg M N Behrens; Christopher M Smith; Simon P Forehan; Ian A Parish; Gayle M Davey; Nicholas S Wilson; Francis R Carbone; Jose A Villadangos
Journal:  Immunol Rev       Date:  2004-06       Impact factor: 12.988

4.  pH-triggered microparticles for peptide vaccination.

Authors:  W Nicholas Haining; Daniel G Anderson; Steven R Little; Michael S von Bergwelt-Baildon; Angelo A Cardoso; Pedro Alves; Kostas Kosmatopoulos; Lee M Nadler; Robert Langer; Daniel S Kohane; Michael S von Berwelt-Baildon
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

5.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

6.  Presentation of exogenous antigen with class I major histocompatibility complex molecules.

Authors:  K L Rock; S Gamble; L Rothstein
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

7.  Defective presentation of endogenous antigen by a cell line expressing class I molecules.

Authors:  N A Hosken; M J Bevan
Journal:  Science       Date:  1990-04-20       Impact factor: 47.728

Review 8.  New tools for antigen delivery to the MHC class I pathway.

Authors:  Gabriel Morón; Gilles Dadaglio; Claude Leclerc
Journal:  Trends Immunol       Date:  2004-02       Impact factor: 16.687

9.  Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines.

Authors:  Steven R Little; David M Lynn; Qing Ge; Daniel G Anderson; Sidharth V Puram; Jianzhu Chen; Herman N Eisen; Robert Langer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

10.  Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.

Authors:  M J Bevan
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

View more
  113 in total

1.  An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis.

Authors:  Jonathan J Cho; Joshua M Stewart; Theodore T Drashansky; Maigan A Brusko; Ashley N Zuniga; Kyle J Lorentsen; Benjamin G Keselowsky; Dorina Avram
Journal:  Biomaterials       Date:  2017-07-24       Impact factor: 12.479

2.  Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination.

Authors:  Chiara Nembrini; Armando Stano; Karen Y Dane; Marie Ballester; André J van der Vlies; Benjamin J Marsland; Melody A Swartz; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

3.  Quantitative aspects of intracellularly-targeted drug delivery.

Authors:  David Stepensky
Journal:  Pharm Res       Date:  2010-09-02       Impact factor: 4.200

Review 4.  Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.

Authors:  Benjamin G Keselowsky; Chang Qing Xia; Michael Clare-Salzler
Journal:  Hum Vaccin       Date:  2011-01-01

5.  Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.

Authors:  Sean M Geary; Qiaohong Hu; Vijaya B Joshi; Ned B Bowden; Aliasger K Salem
Journal:  J Control Release       Date:  2015-09-08       Impact factor: 9.776

6.  Lipid nanocapsule as vaccine carriers for his-tagged proteins: evaluation of antigen-specific immune responses to HIV I His-Gag p41 and systemic inflammatory responses.

Authors:  Saurabh Wadhwa; Anekant Jain; Jerold G Woodward; Russell J Mumper
Journal:  Eur J Pharm Biopharm       Date:  2011-10-31       Impact factor: 5.571

7.  Comparison of PLA microparticles and alum as adjuvants for H5N1 influenza split vaccine: adjuvanticity evaluation and preliminary action mode analysis.

Authors:  Weifeng Zhang; Lianyan Wang; Yuan Liu; Xiaoming Chen; Jiahui Li; Tingyuan Yang; Wenqi An; Xiaowei Ma; Ruowen Pan; Guanghui Ma
Journal:  Pharm Res       Date:  2013-10-30       Impact factor: 4.200

8.  The uptake and intracellular fate of PLGA nanoparticles in epithelial cells.

Authors:  Malgorzata S Cartiera; Katherine M Johnson; Vanathy Rajendran; Michael J Caplan; W Mark Saltzman
Journal:  Biomaterials       Date:  2009-02-20       Impact factor: 12.479

9.  ANALYSIS OF DENDRITIC CELL STIMULATION UTILIZING A MULTI-FACETED NANOPOLYMER DELIVERY SYSTEM AND THE IMMUNE MODULATOR 1-METHYL TRYPTOPHAN.

Authors:  Kevin P Nikitczuk; Edmund C Lattime; Rene S Schloss; Martin L Yarmush
Journal:  Nano Life       Date:  2010-09-01

10.  Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation.

Authors:  Nicholas M Molino; Amanda K L Anderson; Edward L Nelson; Szu-Wen Wang
Journal:  ACS Nano       Date:  2013-10-09       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.